Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical
THE OPPORTUNITY AEM Assets is Adobes digital asset management platform - a Gartner-ranked Leader in Digital Asset Management for over a decade, with agentic AI already shipped and in production: Content Advisor for conversational search, Governance
THE OPPORTUNITY AEM Assets is Adobes digital asset management platform - a Gartner-ranked Leader in Digital Asset Management for over a decade, with agentic AI already shipped and in production: Content Advisor for conversational search, Governance
Unternehmensbeschreibung Die Protectas Gruppe Schweiz ist eine Tochtergesellschaft der weltweit tätigen Securitas AB Gruppe, einem führenden Sicherheitsunternehmen. Zu unseren wichtigsten Dienstleistungen weltweit gehören spezialisierte Überwachung, mobile Sicherheitsdienste, Monitoring, technische Lösungen und Beratung. Wir sind stolz darauf,
About the Company The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in
Unternehmensbeschreibung Die Protectas Gruppe Schweiz ist eine Tochtergesellschaft der weltweit tätigen Securitas AB Gruppe, einem führenden Sicherheitsunternehmen. Zu unseren wichtigsten Dienstleistungen weltweit gehören spezialisierte Überwachung, mobile Sicherheitsdienste, Monitoring, technische Lösungen und Beratung. Wir sind stolz darauf,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
The Opportunity Join the Agentic Outcome Engineering team to help enterprise customers succeed with AI‑powered search and discovery. As an Agentic Outcome Engineer specializing in Adobe Brand Visibility (ABV), you’ll combine technical expertise, customer success skills,
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
About the Company The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in
The Opportunity Adobe Experience Manager (AEM) Assets is Adobes Digital Asset Management platform - an Analyst- and Market-ranked Leader in the category for over a decade, serving top Fortune 100 and 500 customers across segments. AEM
THE OPPORTUNITY Do you understand how marketing and content teams actually work — and do you want to build the system that recommends what they should do next? The Adobe Experience Manager Sites team is building
THE OPPORTUNITY Do you understand how marketing and content teams actually work, and do you want to build the system that tells them what to do next? The Adobe Experience Manager Sites team is building the
Darauf kannst du dich freuen. Du gestaltest die Zuverlässigkeit unserer Züge aktiv mit und trägst dazu bei, dass unsere Kund:innen sicher und pünktlich ankommen. Dich erwartet ein kollegiales Umfeld, in dem Wissen gerne geteilt wird und